FIELD: medicine, oncology, pharmacy. SUBSTANCE: method of inhibition of tumor cells growth involves a stage where tumor cells are subjected for effect of effective dose of composition containing tocotrienol and ionon or statin and ionon or tocotrienol, statin and ionon. Method of inhibition of tumor growth involves a stage where patient is subjected for effect of effective dose of composition including at least one tocotrienol and at least one ionon, or at least one tocotrienol, at least one statin and at least one ionon, or at least one statin and at least one ionon. Invention relates to pharmaceutical composition containing effective dose or at least one tocotrienol and at least one ionon, or at least one tocotrienol, at least one statin and at least one ionon, or at least one statin and at least one ionon. The claimed combinations of active components of composition in its use provides synergistic effect. EFFECT: enhanced effectiveness of treatment of patients, decreased safety of chemotherapy. 15 cl, 4 dwg, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
LIPOSOME DELIVERY OF COMPOSITIONS BASED ON VITAMIN E | 2002 |
|
RU2328273C2 |
MODIFIED DENDRITE CELLS AND THEIR USE IN TREATMENT OF MALIGNANT TUMOURS | 2008 |
|
RU2484132C2 |
METHOD FOR INHIBITION OF MELANOMA GROWTH IN TUMOUR-BEARING MICE | 2023 |
|
RU2813701C2 |
MODIFIED DENDRITIC CELLS AND USE THEREOF IN TREATING MALIGNANT TUMOURS | 2017 |
|
RU2711606C2 |
PHARMACEUTICAL COMPOSITION OF N,N'-BIS(2,3-BUTADIENYL)-1,4-BUTANE-DIAMINE AND METHODS FOR USING IT | 2007 |
|
RU2448693C2 |
BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
MODIFIED DENDRITIC CELLS AND THEIR APPLICATION FOR MALIGNANT TUMOURS TREATMENT | 2013 |
|
RU2644210C2 |
METHOD FOR CREATING POLYNEOPLASIA WITH STIMULATION OF TUMOR GROWTH IN CONDITIONS OF PRIMARY IMMUNODEFICIENCY IN EXPERIMENT | 2021 |
|
RU2751930C1 |
A METHOD FOR MODELING THE PRIMARY MULTIPLE GROWTH OF MALIGNANT TUMORS WITH THE SUPPRESSION OF ONE TUMOR BY ANOTHER IN THE CONDITIONS OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2750127C1 |
DNA-VACCINE AGAINST TUMORAL GROWTH AND WAYS OF THEIR APPLICATION | 2004 |
|
RU2343195C2 |
Authors
Dates
2002-02-20—Published
1998-02-23—Filed